The Influence Of GIP (Glucose-Dependent Insulinotropic Polypeptide) Infusion On Human Adipose Tissue: An In Vivo Study

Adipose Tissue Clinical Trial

Official title:

The Influence Of GIP (Glucose-Dependent Insulinotropic Polypeptide) Infusion On Hormone Sensitive Lipase, Lipoprotein Lipase And Adipokine Expression In Human Subcutaneous Adipose Tissue: An In Vivo Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00809029
• Other study ID #: 08/H1001/20
• Secondary ID: 08DE001
• Status: Recruiting
• Phase: N/A
• First received: December 15, 2008
• Last updated: December 20, 2011
• Start date: April 2011
• Est. completion date: December 2012

Study information

• Verified date: December 2011
• Source: Aintree University Hospitals NHS Foundation Trust
• Contact: CHRISTINA DAOUSI, MD FRCP
• Phone: +44 (0) 151 529 5920
• Email: cdaousi[@]liverpool.ac.uk
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Study part-1

GIP (glucose-dependent insulinotropic polypeptide) is one of the two main incretin hormones secreted by specialized cells of the gastrointestinal tract in response to ingestion of nutrients. Data emerging from studies in animal models and cultured human fat cells support a physiological role for GIP in the adipose tissue metabolism which may contribute to the pathogenesis of obesity.

The proposed study will shed more light on the interactions between gut hormones and adipose tissue. For this pilot study, male subjects fulfilling the inclusion criteria will be given GIP or placebo infusions in a randomized manner. Fat tissue biopsies will be obtained from all subjects during both visits, once in the basal state (before the start of the peptide/placebo infusion) and then repeated at the end of the period of infusion.

Study part-2

Surgery represents the most effective therapeutic modality for morbid obesity. Resolution of type 2 diabetes mellitus (T2DM) has been consistently observed as an additional benefit of surgical treatment of obesity. The mechanisms underlying the dramatic effects of surgery on insulin sensitivity and β-cell function are poorly understood. Bariatric surgery (gastric bypass) promotes changes in the enteroendocrine system as a result of nutrient diversion from the physiological intestinal routes with subsequent profound modification of gut hormone secretion

We hypothesize that restoration of GIP action after bariatric procedures plays a cardinal role in the improvement and/or restoration of diabetes, we propose to study patients (both sex)with morbid obesity and T2DM within 3 months after their surgery. Their responses will be compared to those of BMI matched control subjects with normal glucose tolerance

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Lean (BMI 20-25 kg/m2) subjects with normal glucose tolerance

• Obese (BMI >30 kg/m2) subjects also with normal glucose tolerance.

• Obese with impaired glucose tolerance

• Obese with diet controlled diabetes mellitus

• Morbid obesity, type diabetes and post bariatric surgery (study part 2)

Exclusion Criteria:

• History of severe cardiac, hepatic or renal disease

• Thyroid dysfunction (hyper-or hypothyroidism), or other endocrine disturbance (acromegaly, growth hormone deficiency, hypoadrenalism or cortisol overproduction)

• Current malignant disease

• Known alcohol misuse

• Major psychiatric disease (including current use of antidepressants)

• History of major eating disorder (anorexia or bulimia nervosa)

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Adipose Tissue

Intervention

Other:
• GIP (glucose dependent insulinotropic peptide) infusion
an intravenous infusion of GIP (glucose dependent insulinotropic peptide)or placebo will be administered at a rate of 2 pmol/kg/min and maintained for 240 minutes.

Locations

Country	Name	City	State
United Kingdom	University Hospital Aintree	Liverpool

Sponsors (1)

Lead Sponsor	Collaborator
Aintree University Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To measure Lipoprotein lipase (LPL) and Hormone sensitive Lipase (HSL) activity in adipose tissue		Before and after 4 hours of infusion	No
Secondary	To determine the role of GIP in adipocytokine gene expression and secretion from human subcutaneous adipose tissue		Baseline and after 4 hours of continuous infusion	No